High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1636645
An update on the biology and management of dyskeratosis congenita and related telomere biology disorders
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1662720
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1649132
Platelet function assays in diagnosis: an update
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1562333
Overcoming challenges of venous thromboembolism in sickle cell disease treatment
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1583554
Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1562331
Considering the spleen in sickle cell disease
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1627192
A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1605288
Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1640599
The role of regulatory T cells in graft-versus-host disease management
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1709436
Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1575130
The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1617129
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1645004
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1593824
Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1602036
Novel therapies in low- and high-risk myelodysplastic syndrome
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1647778
Quality of life in multiple myeloma: considerations and recommendations
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1613886
Management of antithrombin deficiency: an update for clinicians
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1611424
Switching patients in the age of long-acting recombinant products?
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2018.1564032
Management of aplastic anemia after failure of frontline immunosuppression
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1645003
An update on: molecular genetics of high-risk chronic lymphocytic leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1697225
Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1596793
Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1676716
Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1560259
Current and emerging treatments for immune thrombocytopenia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1636644
Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1652590
Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1619170
Emicizumab for hemophilia A without inhibitors
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1624519
Contemporary management of essential thrombocythemia in children
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1602034
Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1660640
Improving fibrinolysis in venous thromboembolism: impact of fibrin structure
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1627193
Timing treatment for smoldering myeloma: is earlier better?
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1599281
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1643232
Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1677152
Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1643231
When to use stem cell transplant in mantle cell lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1588106
Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1547189
Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1645002
Tranexamic acid for childbirth: why, when, and for whom
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1642744
Umbilical cord blood transplantation and the impact of the CTLA4 genotype on outcomes
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1680281
BRAF in the cross-hairs
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1583553
Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1690987
An update on treatment of higher risk myelodysplastic syndromes
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2018.1537777
What are the implications of cost for myeloma therapy?
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1682545
An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1623666
An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1658522
Current perspectives on the treatment of double hit lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1623020
Blinatumomab: a novel therapy for the treatment of non-Hodgkin’s lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1676717
Myelofibrosis: best practices, controversies and 2019 update
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1691519
Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1668763